Investment Thesis
Severe data quality issues undermine confidence in reported profitability metrics (gross margin 595.9% exceeds 100%, indicating mathematical impossibility). Excluding suspicious margin data, company shows strong balance sheet and FCF generation, but weak fundamentals including 4.3% revenue growth and declining net income present headwinds.
Strengths
- Exceptional balance sheet with minimal debt (0.01x D/E ratio) and $3.6B cash
- Strong free cash flow generation ($1.1B annually, 76.5% FCF margin)
- Solid operating cash flow ($1.6B) demonstrates earnings quality
Risks
- Critical data integrity issues: gross profit exceeds revenue (mathematically impossible)
- Anemic revenue growth (4.3% YoY) with net income declining 0.6% YoY
- Liquidity deterioration: quick ratio 0.80x below 1.0 threshold; current ratio barely adequate at 1.04x
Key Metrics to Watch
- Revenue growth trajectory and pharmaceutical segment performance
- Gross profit and margin reconciliation with audited 10-K filing
- Working capital trends and quick ratio improvement
Financial Metrics
Revenue
1.5B
Net Income
1.4B
EPS (Diluted)
$1.21
Free Cash Flow
1.1B
Total Assets
40.7B
Cash
3.6B
Profitability Ratios
Gross Margin
595.9%
Operating Margin
143.8%
Net Margin
94.0%
ROE
17.8%
ROA
3.5%
FCF Margin
76.5%
Balance Sheet & Liquidity
Current Ratio
1.04x
Quick Ratio
0.80x
Debt/Equity
0.01x
Debt/Assets
80.6%
Interest Coverage
2.35x
Long-term Debt
40.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-17T08:39:27.089032 |
Data as of: 2025-12-31 |
Powered by Claude AI